173 related articles for article (PubMed ID: 12091148)
1. Inefficacy of rituximab in a case of low grade non-Hodgkin's lymphoma with cryoglobulinemia.
Baronciani D; Angelucci E; Gaziev J; Visani G
Haematologica; 2002 Jul; 87(7):ELT33. PubMed ID: 12091148
[No Abstract] [Full Text] [Related]
2. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
3. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
[No Abstract] [Full Text] [Related]
4. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
5. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
6. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
7. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
Akhtar S; Maghfoor I
J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496
[No Abstract] [Full Text] [Related]
8. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
Gajra A; Vajpayee N; Grethlein SJ
Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
[TBL] [Abstract][Full Text] [Related]
9. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
10. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
Williams ME
Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271
[No Abstract] [Full Text] [Related]
11. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
[TBL] [Abstract][Full Text] [Related]
12. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed.
Prescrire Int; 2003 Aug; 12(66):125-6. PubMed ID: 12906019
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
16. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.
Mielke F; Schneider-Obermeyer J; Dörner T
Ann Rheum Dis; 2008 Jul; 67(7):1056-7. PubMed ID: 18556453
[No Abstract] [Full Text] [Related]
17. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of hepatitis B virus with rituximab.
Tsutsumi Y; Kanamori H; Mori A; Tanaka J; Asaka M; Imamura M; Masauzi N
Expert Opin Drug Saf; 2005 May; 4(3):599-608. PubMed ID: 15934864
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
20. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.
Wasmuth JC; Fischer HP; Sauerbruch T; Dumoulin FL
Eur J Med Res; 2008 Oct; 13(10):483-6. PubMed ID: 19008178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
